Summary of clinical and genetic data of H pylori–negative gastric MALT lymphoma
| Case no. . | Sex . | Age (y) . | Staging* . | Methods for H pylori detection . | Antibiotic therapy . | Other treatment and follow-up . | t(11;18) . | MALT1 breakpoint† . | BCL10 expression . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 63 | IVE | His/serology | ND | Partial gastrectomy because of gastric ulcer (presence of MALT lymphoma on review) in 1982; lymphoma relapsed in the gastric stump and lung in 2001 and treated with rituximab; alive, PR, follow-up for 18 mo | + | 1150 | Nuc |
| 2 | M | 67 | IVE | His/serology | ND | Partial gastrectomy because of gastric ulcer (presence of MALT lymphoma on review) in 1985; lymphoma relapsed in gastric stump, colon, and terminal ileum in 2001, treated with rituximab; alive, stable disease, follow-up for 23 mo | + | 814 | Nuc |
| 3 | M | 57 | IIE | His/serology | ND | Chemotherapy, alive, CR, follow-up for 42 mo | + | 1123 | Nuc |
| 4 | M | 74 | IE | His/serology | ND | New case, follow-up not available | + | 1123 | Nuc |
| 5 | F | 65 | IIE | His/serology/CLO | ND | New case, follow-up not available | + | 1123 | Nuc |
| 6 | F | 38 | IIE | His/serology | ND | CHOP therapy (9 courses); alive, CR, follow-up for 46 mo | + | 814 | Cyt |
| 7 | M | 55 | NA | His/CLO | ND | NA | + | 1123 | Nuc |
| 8 | M | 60 | IE | His/serology | NR, 4 mo | Total gastrectomy; alive, CR, follow-up for 50 mo | + | 814 | ND |
| 9 | M | 51 | IE | His/serology | NR, 4.5 mo | Total gastrectomy because of bleeding, relapsed in lung after 36 mo, salvaged with chemotherapy; alive, CR, follow-up for 70 mo | + | 1123 | Nuc |
| 10 | F | 50 | IE | His/serology | NR, 12 mo | Radiotherapy; alive, CR, follow-up for 12 mo | − | NA | Cyt |
| 11 | F | 45 | IE | His/serology | NR, 9.5 mo | Total gastrectomy; alive, CR, follow-up for 42 mo | − | NA | Nuc |
| 12 | M | 45 | IE | His/serology | NR, NA | No other treatment; alive, follow-up for 13 mo | − | NA | Cyt |
| 13 | M | 53 | IE | His/serology | ND | Chemotherapy, lymphoma relapsed and salvaged by radiotherapy; alive, CR, follow-up for 40 mo | − | NA | ND |
| 14 | M | 64 | IVE | His/serology | ND | Concurrent gastric and small intestinal MALT lymphoma, chemotherapy; alive, CR, follow-up for 16 mo | − | NA | ND |
| 15 | M | 70 | IE | His/serology | ND | NA | − | NA | Nuc |
| 16 | F | 45 | IE | His/serology | ND | Partial gastrectomy; new case, follow-up not available | − | NA | Nuc |
| 17 | M | 57 | IE | His/serology | ND | NA | − | NA | Nuc (strong) |
| Case no. . | Sex . | Age (y) . | Staging* . | Methods for H pylori detection . | Antibiotic therapy . | Other treatment and follow-up . | t(11;18) . | MALT1 breakpoint† . | BCL10 expression . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 63 | IVE | His/serology | ND | Partial gastrectomy because of gastric ulcer (presence of MALT lymphoma on review) in 1982; lymphoma relapsed in the gastric stump and lung in 2001 and treated with rituximab; alive, PR, follow-up for 18 mo | + | 1150 | Nuc |
| 2 | M | 67 | IVE | His/serology | ND | Partial gastrectomy because of gastric ulcer (presence of MALT lymphoma on review) in 1985; lymphoma relapsed in gastric stump, colon, and terminal ileum in 2001, treated with rituximab; alive, stable disease, follow-up for 23 mo | + | 814 | Nuc |
| 3 | M | 57 | IIE | His/serology | ND | Chemotherapy, alive, CR, follow-up for 42 mo | + | 1123 | Nuc |
| 4 | M | 74 | IE | His/serology | ND | New case, follow-up not available | + | 1123 | Nuc |
| 5 | F | 65 | IIE | His/serology/CLO | ND | New case, follow-up not available | + | 1123 | Nuc |
| 6 | F | 38 | IIE | His/serology | ND | CHOP therapy (9 courses); alive, CR, follow-up for 46 mo | + | 814 | Cyt |
| 7 | M | 55 | NA | His/CLO | ND | NA | + | 1123 | Nuc |
| 8 | M | 60 | IE | His/serology | NR, 4 mo | Total gastrectomy; alive, CR, follow-up for 50 mo | + | 814 | ND |
| 9 | M | 51 | IE | His/serology | NR, 4.5 mo | Total gastrectomy because of bleeding, relapsed in lung after 36 mo, salvaged with chemotherapy; alive, CR, follow-up for 70 mo | + | 1123 | Nuc |
| 10 | F | 50 | IE | His/serology | NR, 12 mo | Radiotherapy; alive, CR, follow-up for 12 mo | − | NA | Cyt |
| 11 | F | 45 | IE | His/serology | NR, 9.5 mo | Total gastrectomy; alive, CR, follow-up for 42 mo | − | NA | Nuc |
| 12 | M | 45 | IE | His/serology | NR, NA | No other treatment; alive, follow-up for 13 mo | − | NA | Cyt |
| 13 | M | 53 | IE | His/serology | ND | Chemotherapy, lymphoma relapsed and salvaged by radiotherapy; alive, CR, follow-up for 40 mo | − | NA | ND |
| 14 | M | 64 | IVE | His/serology | ND | Concurrent gastric and small intestinal MALT lymphoma, chemotherapy; alive, CR, follow-up for 16 mo | − | NA | ND |
| 15 | M | 70 | IE | His/serology | ND | NA | − | NA | Nuc |
| 16 | F | 45 | IE | His/serology | ND | Partial gastrectomy; new case, follow-up not available | − | NA | Nuc |
| 17 | M | 57 | IE | His/serology | ND | NA | − | NA | Nuc (strong) |
His, histology; ND, not done; PR, partial remission; Nuc, nuclear; CR, complete remission; CHOP, a regimen of cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), and prednisolone; Cyt, cytoplasmic; NA, not available; NR, no response; +, t(11;18) positive; –, t(11;18) negative.
According to the Ann Arbor system modified by Musshoff.